Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 11/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25879214 | 0.92 | CFD (0.46) | CFDFFAR1PLGPLAUF11 | |
| SCHEMBL25879274 | 0.90 | CFD (0.45) | CFDFFAR1PLGPLAUF11 | |
| SCHEMBL21437456 | 0.89 | CFD (0.45) | CFD | |
| SCHEMBL25878852 | 0.89 | CFD (0.55) | CFDPLGPLAUF11KLKB1 | |
| SCHEMBL25879272 | 0.87 | CFD (0.51) | CFDFFAR1PLGPLAUF11 | |
| SCHEMBL21438661 | 0.86 | CFD (0.59) | CFDFFAR1PLGPLAUF11 | |
| SCHEMBL25883047 | 0.85 | CFD (0.41) | CFDPOLB | |
| SCHEMBL25879283 | 0.85 | CFD (0.46) | CFDFFAR1THRATHRBHSD17B10 | |
| SCHEMBL21438035 | 0.82 | CFD (0.45) | CFDFFAR1PLGPLAUF11 | |
| SCHEMBL21455470 | 0.82 | CFD (0.37) | CFDTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | CFD 17/4885FFAR1 3926/4885PLG 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.